Remedent, Inc.
Remedent, Inc.
Your view on REMI
Overview
What the company does, where it operates, and who runs it.
About Remedent, Inc.
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Guy De Vreese
- Headquarters
- Zuiderlaan 1-3, Gent, BE
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
- CEO
- Guy De Vreese
- Headquarters
- Zuiderlaan 1-3, Gent, BE
Remedent, Inc., through its subsidiaries, researches, designs, develops, manufactures, and distributes oral care and cosmetic dentistry products. It primarily provides professional veneers and teeth whitening products for professional and over-the-counter use.
The company offers River8, a prefab veneer that enables the dentist to find the right combination of teeth for a patient with minor reshaping. It also provides GlamSmile veneers, which are ultra-thin claddings attached to the front of the patient's teeth.
In addition, the company offers SmileMe Mirror, an integrated marketing concept for the dental practice, which enables dentists to offer smile consultation in approximately 10 minutes; SmileSketch, a simulation software to make a sketch of what the patient could look like; and various Treatment Pages to explain the benefits of certain treatments, as well as Condor, an intra-oral 3D scanner.
Further, it provides dental implant solutions and treatment concepts. The company sells its products to dental professionals in approximately 30 countries, including Asia, Europe, the Middle East, Canada, and the United States through its internal sales force and third party distributors.
The company was founded in 1986 and is headquartered in Ghent, Belgium.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Remedent, Inc., and the rating behind it. REMI last traded at $0.0007; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Remedent, Inc.. Starting points for Remedent, Inc.: EPS -$0.01, beta -0.49 — an Medical - Instruments & Supplies name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Remedent, Inc.. Remedent, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Remedent, Inc.. Trailing twelve-month EPS for Remedent, Inc. stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Remedent, Inc.. Remedent, Inc. has reported as a listed company since 2006. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Remedent, Inc. valued side by side against its closest peers. Remedent, Inc. is measured against Medical - Instruments & Supplies peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Remedent, Inc., and how their positions are changing. At a $13,997 market value, institutional positions materially move Remedent, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Remedent, Inc. executives and directors. Shares of Remedent, Inc. have traded between $0.0002 and $0.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Remedent, Inc.. Remedent, Inc. is a $13,997 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Remedent, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Remedent, Inc.. Coverage tracks Remedent, Inc. within Medical - Instruments & Supplies (Healthcare). Press releases and market coverage, newest first.